Clinical trials
Multiple Sclerosis (MS) - Relapsing-remitting clinical trials
Below are recruiting multiple sclerosis (ms) - relapsing-remitting clinical trials, each written for real people, not researchers. We’re tracking 233 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05983809Recruiting
Balance and walking rehab using technology for MS
This trial tests a new type of balance and walking training for people with multiple sclerosis. It uses technology to help improve your stability and gait, which may help you move more safely and confidently.
Roma, RMAges 18–65 - NCT06495138Recruiting
Eye exercises for dizziness in multiple sclerosis
This study tests a new type of eye exercise to help with dizziness and balance problems in people with multiple sclerosis (MS). The exercise involves moving your head and eyes in a specific way to retrain your balance system.
Atlanta, GeorgiaAges 18–89 - NCT06782724RecruitingPhase 2
Psilocybin therapy for distress in advanced illness
This trial tests whether a single dose of psilocybin (a psychedelic medicine) can help reduce depression and distress in people with advanced lung disease, ALS, multiple sclerosis, or Parkinson's. You would receive preparation, the drug, and follow-up support in a safe, supervised setting.
PragueAges 18 years+ - NCT06780150Recruiting
Ocrelizumab effects on nerve health and satisfaction in MS
This study looks at how ocrelizumab treatment affects a nerve health marker called neurofilament light chain (NfL) and how satisfied you are with the treatment. It may help doctors understand if this medicine works well for people with multiple sclerosis.
AachenAges 18 years+ - NCT06249438RecruitingPhase 1
CAR-T cell therapy for hard-to-treat autoimmune diseases
This trial tests a new CAR-T cell therapy (C-CAR168) for people with several autoimmune diseases that have not responded to standard treatments. It aims to see if this therapy can control the disease when other medicines have failed.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06733922RecruitingPhase 4
Tracking MS changes with ofatumumab in active relapsing MS
This study looks at whether blood tests and eye-tracking tasks can show how well ofatumumab slows or stops MS damage. It's for people starting ofatumumab as part of their regular care who have active relapsing-remitting MS.
Calgary, AlbertaAges 18–99 - NCT06675955RecruitingPhase 3
Extension study to keep taking ocrelizumab for multiple sclerosis
This extension study continues treatment with ocrelizumab for people with multiple sclerosis who are already taking it as part of a parent trial, to see how MS affects physical function over a longer time. It helps ensure you can keep receiving ocrelizumab even if it's not available where you live.
Amiens Cedex1Ages 18 years+ - NCT06676618Recruiting
Exercise training for multiple sclerosis patients
This study tests a multimodal exercise program for people with multiple sclerosis. It aims to improve mobility, strength, and overall well-being through guided exercises you can do at home.
Istanbul, BuyukcekmeceAges 20–65 - NCT05124600Recruiting
Personalized MS app study for 21-day daily use
This study looks at an individualized health eLibrary app for people with multiple sclerosis (MS). You may use the app for 21 days and help researchers compare outcomes between a group using the app and a comparison group.
Champaign, IllinoisAges 18 years+ - NCT06592703RecruitingPhase 1
Stem cells for primary progressive MS
This study tests whether stem cells from donated fat tissue can slow down primary progressive multiple sclerosis. You would receive a single injection of the cells into your spinal fluid and be followed for up to 2 years.
CréteilAges 18–55 - NCT06486779Recruiting
Study of Kesimpta in Greek MS Patients
This study watches how well Kesimpta (ofatumumab) works for people with relapsing multiple sclerosis over time. It collects information from routine doctor visits and scans to see if the treatment is controlling the disease.
Athens, AtticaAges 18–55 - NCT06463743RecruitingPhase 2
Metformin for aging people with MS
This study tests whether metformin, a common diabetes drug, can help people with multiple sclerosis (MS) as they age. It may be used alone or added to your current MS treatment, and the goal is to see if it slows down aging-related changes in MS.
Buffalo, New YorkAges 55–75 - NCT06441617Enrolling by invitation
Online program to reduce fatigue in multiple sclerosis
This trial tests an online self-management program to help reduce fatigue in people with MS. You'll use a website or app over 24 weeks, and researchers will check how well it works.
Washington D.C., District of ColumbiaAges 22 years+ - NCT06433752Recruiting
Study of BRIUMVI for relapsing multiple sclerosis
This study looks at how well BRIUMVI (a medicine for relapsing multiple sclerosis) works for people in everyday life. Researchers want to see how people do when they first start the medication.
Birmingham, AlabamaAges 18 years+ - NCT06433765Recruiting
BRIUMVI and pregnancy safety in multiple sclerosis
This study looks at the effects of the MS medication BRIUMVI on pregnancy and baby health. It compares women who took BRIUMVI during pregnancy to those who did not.
Wilmington, North CarolinaAges 15–50 - NCT06341023Recruiting
Balance training for older adults with MS
This study tests a balance training program for people with MS who have mild walking and memory difficulties. It aims to improve balance and prevent falls.
Chicago, IllinoisAges 18–90 - NCT04121468RecruitingPhase 1/Phase 2
Metformin trial for vision nerve recovery in young people with MS
This study tests whether metformin can help “reset” damaged nerve cells in the brain and improve vision-related nerve problems in children and young adults with multiple sclerosis. Participants are assigned to metformin or a comparison treatment in a blinded (not everyone knows which) study.
Toronto, OntarioAges 10–25 - NCT06261489RecruitingPhase 2
Cannabis for bladder problems in multiple sclerosis
This study tests whether cannabis, with either THC or CBD, helps with bladder and urinary symptoms caused by multiple sclerosis. It compares two types of cannabis to see which works better.
Calgary, AlbertaAges 26–59 - NCT06197685Recruiting
Combining treatments to improve memory in multiple sclerosis
This trial tests a combination of two approaches to help people with MS improve memory and learning. If you have mild-to-moderate mobility issues and are not very active, you may be able to join.
East Hanover, New JerseyAges 18–70 - NCT06164483Recruiting
Hearing tests in people with MS or Parkinson's
This study checks how well people with multiple sclerosis (MS) or Parkinson's disease hear. It uses simple hearing tests to see if these conditions affect hearing.
Catania, SicilyAges 20–40 - NCT06170970RecruitingPhase 2
Solriamfetol for fatigue in multiple sclerosis
This study tests whether solriamfetol, a medication that promotes wakefulness, can reduce fatigue in people with multiple sclerosis. If you struggle with tiredness and sleepiness, this trial may help you understand how this drug works for MS-related fatigue.
Baltimore, MarylandAges 18–60 - NCT06136728RecruitingPhase 3
Dalfampridine and physical therapy for walking problems in MS
This trial tests whether adding dalfampridine to physical therapy helps people with multiple sclerosis walk better. You must not already be taking dalfampridine or getting physical therapy to join.
Boston, MassachusettsAges 25–75 - NCT06138132RecruitingPhase 1
CAR-T cell therapy for progressive multiple sclerosis
This trial is testing a type of immunotherapy called CAR-T cells (made from your own immune cells) to see if it can help slow or stop progressive multiple sclerosis. It is a very early safety study, so only people with progressive MS who meet strict health criteria can join.
Palo Alto, CaliforniaAges 18–65 - NCT05754593Recruiting
Study ovarian reserve in women with multiple sclerosis
This study compares egg supply (“ovarian reserve”) in women with multiple sclerosis to women without MS. It may help doctors understand how MS affects reproductive health and egg supply.
BordeauxAges 25–35
Hear when a new Multiple Sclerosis (MS) - Relapsing-remitting trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for multiple sclerosis (ms) - relapsing-remitting?
- Yes. Clin2 currently lists 233 recruiting multiple sclerosis (ms) - relapsing-remitting studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a multiple sclerosis (ms) - relapsing-remitting trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a multiple sclerosis (ms) - relapsing-remitting trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.